Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enhancing rAAV vector expression in the lung.

Isabel Virella-Lowell1, Benjamin Zusman, Kevin Foust

  • 1Department of Pediatrics of the University of Florida College of Medicine, USA.

The Journal of Gene Medicine
|April 20, 2005
PubMed
Summary

Recombinant adeno-associated virus (rAAV) gene therapy for cystic fibrosis (CF) lung disease shows improved expression with rAAV1 and rAAV5 serotypes. These serotypes, combined with optimized promoters, enhance gene transfer efficiency in airway cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of dental diseases with pulmonary outcomes in a multicenter cohort of adolescents and young adults with CF.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

The dose makes the poison: Mechanisms of cytotoxicity of high-dose AAV vectors.

Molecular therapy. Advances·2026
Same author

Optimization of Alpha-1 Antitrypsin Expression from Adeno-Associated Virus Vectors.

Human gene therapy·2026
Same author

Letter to the Editor. Intrathalamic gene delivery.

Journal of neurosurgery·2026
Same author

Immune Toxicities in AAV Gene Therapy: Overview for Clinicians.

International journal of molecular sciences·2026

Area of Science:

  • Gene Therapy
  • Molecular Virology
  • Pulmonary Medicine

Background:

  • Gene expression from recombinant adeno-associated virus serotype 2 (rAAV2) vectors in the lung for cystic fibrosis (CF) gene therapy is variable.
  • This variability is partly due to the large size of the CF transmembrane regulator (CFTR) coding sequence, requiring compact promoters over stronger ones.

Purpose of the Study:

  • To improve gene expression from rAAV vectors in the lung for CF gene therapy.
  • To evaluate the efficacy of AAV capsid serotypes with greater tropism for airway cell apical surfaces (rAAV5, rAAV1) and strong promoters (CMV enhancer/chicken beta-actin hybrid [Cbeta]).

Main Methods:

  • Assessed promoter activity (CMV immediate-early [CMVie], Cbeta, Cbeta with woodchuck hepatitis virus post-transcriptional regulatory element [wpre]) in vitro and in vivo using human alpha-1 antitrypsin (hAAT) reporter.

Related Experiment Videos

  • Compared rAAV serotypes 1, 2, and 5 using the optimized Cbeta-wpre cassette with a luciferase reporter in C57Bl6 mice.

    • Main Results:

    • The Cbeta-AAT-wpre construct achieved high serum hAAT levels (1.5 mg/ml) in vivo.
    • Pulmonary luciferase expression at 8 weeks was similar for rAAV5 (2.9 x 10^6 RLU/g) and rAAV1 (2.7 x 10^6 RLU/g), significantly exceeding rAAV2 levels.

    Conclusions:

    • rAAV1 and rAAV5 serotypes demonstrate enhanced gene transfer efficiency in the lung compared to rAAV2.
    • These serotypes, particularly when combined with optimized promoter cassettes, offer promising alternatives for improving rAAV-mediated gene therapy in the lung.